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Abstract
Objective: To compare the rate of decline of renal function in tenofovir- and abacavir-based antiretroviral therapy (ART) in
low-body weight treatment-naı ¨ve patients with HIV infection.
Design: We conducted a single-center retrospective cohort study of 503 Japanese patients who commenced on either
tenofovir- or abacavir-based initial ART.
Methods: The incidence of renal dysfunction, defined as more than 25% fall in estimated glomerular filtration rate (eGFR)
from the baseline, was determined in each group. The effect of tenofovir on renal dysfunction was estimated by univariate
and multivariate Cox hazards models as the primary exposure. Changes in eGFR until 96 weeks were estimated in both
groups with a repeated measures mixed model.
Results: The median body weight of the cohort was 64 kg. The estimated incidence of renal dysfunction in the tenofovir
and the abacavir arm was 9.84 per 100 and 4.55 per 100 person-years, respectively. Tenofovir was significantly associated
with renal dysfunction by univariate and multivariate analysis (HR=1.747; 95% CI, 1.152–2.648; p=0.009) (adjusted
HR=2.080; 95% CI, 1.339–3.232; p,0.001). In subgroup analysis of the patients stratified by intertertile baseline body
weight, the effect of tenofovir on renal dysfunction was more evident in patients with lower baseline body weight by
multivariate analysis (#60 kg: adjusted HR=2.771; 95%CI, 1.494–5.139; p=0.001) (61–68 kg: adjusted HR=1.908; 95%CI,
0.764–4.768; p=0.167) (.68 kg: adjusted HR=0.997; 95%CI, 0.318–3.121; p=0.995). The fall in eGFR was significantly
greater in the tenofovir arm than the abacavir arm after starting ART (p=0.003).
Conclusion: The incidence of renal dysfunction in low body weight patients treated with tenofovir was twice as high as
those treated with abacavir. Close monitoring of renal function is recommended for patients with small body weight
especially those with baseline body weight ,60 kg treated with tenofovir.
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Introduction
Tenofovir disoproxil fumarate (TDF) and abacavir sulfate
(ABC) are widely used nucleot(s)ide reverse transcriptase inhibitors
(NRTIs) as part of the initial antiretroviral therapy for patients
with HIV infection in the developed countries (URL:http://www.
aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf) (URL:
http://www.europeanaidsclinicalsociety.org/images/stories/EACS-
Pdf/1_treatment_of_hiv_infected_adults.pdf). TDF is generally pre-
ferred to ABC, since ABC is reported to cause serioushypersensitivity
reaction in 5–8% of the patients and its efficacy in viral suppression is
reported to be inferior to TDF among patients with baseline HIV
viral load of .100,000 copies/ml [1,2]. On the other hand, renal
proximal tubular damage and renal dysfunction are well-known
adverse effects of TDF [3–9]. A meta-analysis study that compared
TDF and other NRTIs concluded that the decline in renal function
with TDF use is significant but modest, and the ASSERT study
conducted in Europe compared randomly-selected treatment naı ¨ve
patients who commenced treatment with either TDF or ABC with
efavirenz and showed no difference in estimated glomerular filtration
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29977rate (eGFR) between the two groups at 48 weeks [9,10]. To date, the
nephrotoxicity of TDF have been regarded as mild and tolerable
[2,5–7,9–11].
However, the TDF-related nephrotoxicity has hardly been
evaluated in patients with small body weight, who are potentially
at higher risk for larger drug exposure and thus, more severe
toxicity [12–15]. Indeed, some recent studies including ours
reported a higher incidence of TDF-related renal dysfunction
among Asian patients with low body weight compared with
previous studies on mostly Whites and African Americans with
larger body weight [13,16]. Thus, it is important to provide more
evidence in support of TDF-associated nephrotoxicity in patients
with low body weight since such data can elucidate whether TDF-
related nephrotoxicity is as mild in low-body-weighted patients as
previously reported in Europe and the USA. This is also important
because there is increasing use of TDF in resource-limited settings,
where patients are often of relatively small body weight, following
the revised 2010 WHO guidelines that recommend TDF as one of
the components of first line therapies (URL:http://whqlibdoc.
who.int/publications/2010/9789241599764_eng.pdf)[13,16–19].
To our knowledge, there are no studies that compared renal
function in treatment naı ¨ve Asian patients who commenced
treatment with TDF or ABC.
Based on the above background, the present study was designed
to compare the incidence of renal dysfunction and change in
eGFR between treatment-naı ¨ve Japanese patients with low body
weight who started either TDF or ABC as part of the antiretroviral
regimen.
Methods
Ethics Statement
This study was approved by the Human Research Ethics
Committee of National Center for Global Health and Medicine,
Tokyo. All patients included in this study provided a written
informed consent for their clinical and laboratory data to be used
and published for research purposes. This study has been
conducted according to the principles expressed in the Declaration
of Helsinki.
Study Subjects
We performed a retrospective, single-center cohort study of
HIV-infected Japanese patients using the medical records at the
National Center for Global Health and Medicine, Tokyo, Japan.
Our facility is one of the largest clinics for patients with HIV
infection in Japan with more than 2,700 registered patients. The
study population was treatment-naı ¨ve patients with HIV infection,
aged .17 years, who commenced treatment with either the
recommended 300 mg/day dose of TDF or 600 mg/day dose of
ABC-containing antiretroviral regimen at our clinic between
January 1, 2004 and March 31, 2009. During this inclusion
period, all except two patients at our clinic started ART with
either ABC or TDF. Patients with an eGFR of .60 ml/min/1.73
m
2 were enrolled. Patients were followed up until March 31, 2011.
They were excluded if they started ART with both TDF and ABC,
their follow-up period at our facility was less than 24 weeks after
commencement of ART, or if they had started ART at other
facilities. Only Japanese patients were included in order to
examine a population with comparatively homogenous basic
demographics and background. The attending physician selected
either TDF or ABC at baseline, and the use of these two drugs was
based on the Japanese guidelines, which place both ABC and TDF
as the preferred NRTIs (http://www.haart-support.jp/guide-
line2011.pdf. in Japanese). The attending physician also selected
the key drug [non-nucleoside reverse transcriptase inhibitor
(NNRTI), protease inhibitor (PI), or integrase inhibitor (INI)].
All patients received standard ART with two NRTIs combined
with either PI, NNRTI, or INI.
Measurements
We defined renal dysfunction as more than 25% decrease in
eGFR relative to the baseline [13,16,20,21]. The baseline eGFR
was estimated for each patient from the average of two successive
serum creatinine measurements made closest to and preceding the
commencement of antiretroviral therapy by no more than 90 days.
Changes in eGFR were plotted from the baseline measurement
until the average value of two successive measurements diminished
to less than 75% of the baseline, discontinuation of TDF or ABC,
or at the end of the follow-up period. Discontinuation of TDF and
ABC was the choice of the attending physician, and was based on
virologic failure or ART-related side effects other than renal
dysfunction. Before the initiation of ART and until suppression of
HIV-1 viral load, patients visited our clinic every month.
However, after viral load suppression, the visit interval was
extended up to every three months. Serum creatinine and eGFR
were measured in every visit, and the frequency of measurements
was similar in patients on TDF and ABC. eGFR was calculated
using the equation from the 4-variable Modification of Diet in
Renal Disease (MDRD) study, eGFR=1866 [serum creati-
nine]
21.1546[age]
20.2036[0.742 if patient is female] 6[1.212 if
patient is African American] [22]. In this study, the primary
exposure variable was TDF use over ABC as part of the initial
ART.
The potential risk factors for renal dysfunction were determined
according to previous studies and collected together with the basic
demographics from the medical records [15,23–25]. They
included age, sex, body weight, body mass index, (BMI) = {body
weight (kg) / [(height (m)]
2}, baseline laboratory data (CD4 cell
count, HIV viral load, and serum creatinine), and presence or
absence of other medical conditions (concurrent use of ritonavir-
boosted protease inhibitors, concurrent nephrotoxic drugs such as
ganciclovir, sulfamethoxazole/trimethoprim, and non-steroidal
anti-inflammatory agents, diabetes mellitus defined by using
anti-diabetic agents or fasting plasma glucose .126 mg/dl or
plasma glucose .200 mg/dl on two different days, co-infection
with hepatitis B defined by positive hepatitis B surface antigen, co-
infection with hepatitis C defined by positive HCV viral load,
hypertension defined by current treatment with antihypertensive
agents or two successive measurements of systolic blood pressure
.140 mmHg or diastolic blood pressure .90 mmHg at the clinic,
dyslipidemia defined by current treatment with lipid-lowering
agents, and current smoking). At our clinic, weight and blood
pressure were measured on every visit whereas other variables
were measured in the first visit and at least once annually. We used
the data on or closest to and preceding the day of starting ART by
no more than 90 days.
Statistical analysis
The time to 25% decline in eGFR from the baseline was
calculated from the date of commencement of treatment to the
date of diagnosis of the above-defined renal dysfunction. Censored
cases represented those who discontinued ABC or TDF, dropped
out, were referred to other facilities, or at the end of follow-up
period. The time from the start of ART to .25% decrease in
eGFR was analyzed by the Kaplan Meier method for patients who
started TDF (TDF arm) and ABC (ABC arm), and the log-rank
test was used to determine the statistical significance. The Cox
proportional hazards regression analysis was used to estimate the
TDF Renal Dysfunction in Low Body Weight Patients
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decrease in eGFR relative to the baseline. The impact of each
basic demographics, baseline laboratory data, and other medical
conditions listed above was also estimated with univariate Cox
proportional hazards regression.
To estimate the unbiased prognostic impact of TDF use over
ABC for renal dysfunction, we conducted three models using
multivariate Cox proportional hazards regression analysis. Model
1 was the aforementioned univariate analysis for TDF use over
ABC. Model 2 included age and weight plus model 1 in order to
adjust for basic characteristics. In model 3, we added variables
with P values ,0.05 in univariate analysis for adjustment (these
included age per 1 year, weight per 1 kg decrement, CD4 count
per 1 /ml decrement, HIV viral load per log10/ml, serum
creatinine per 1 mg/dl, concurrent use of nephrotoxic drug(s),
hepatitis B infection, and diabetes mellitus). The eGFR and the
BMI were excluded from multivariate analysis because of their
multicollinearity with age and serum creatinine, and weight,
respectively, since eGFR and BMI are gained by the equation of
those variables [22,26]. We chose to add weight instead of BMI
because our previous work showed that weight was more useful
and handy information to estimate the risk for TDF-related
nephrotoxicity than BMI [16].
As a sensitivity analysis, creatinine clearance was similarly
calculated with Cockcroft-Gault equation for each patient,
creatinine clearance = [(140 - age) 6 weight (kg)] / (serum
creatinine672)(60.85 for females) [27]. Actual body weight was
used for the calculation. The impact of TDF use over ABC for
.25% decrement of creatinine clearance from the baseline was
estimated in univariate analysis and multivariate analysis adjusted
with the before mentioned variables with Cox proportional
hazards model.
To estimate the impact of weight on TDF-related nephrotox-
icity, we did subgroup analysis for intertertile baseline body weight
categories: #60, 61–68, and .68 kg. Then, the abovementioned
multivariate analysis with eGFR was conducted for each
subgroup.
We also used a repeated measures mixed model to estimate and
compare changes in eGFR between ABC and TDF from baseline
to 2 years after initiation of ART by 6-month intervals adjusted for
baseline eGFR and weight [10]. For each patient, the eGFR
values at closest to and preceding 24, 48, 72 and 96 weeks after
commencement of ART were collected. In this analysis, censoring
occurred at discontinuation of TDF or ABC, leaving care, or
reaching the end of the observation period before 96 weeks.
Sensitivity analysis with creatinine clearance calculated by
Cockcroft-Gault equation was similarly conducted.
Statistical significance was defined at two-sided p values ,0.05.
We used hazard ratios (HRs) and 95% confidence intervals (95%
CIs) to estimate the impact of each variable on renal dysfunction.
All statistical analyses were performed with The Statistical Package
for Social Sciences ver. 17.0 (SPSS, Chicago, IL).
Results
The study subjects were 199 patients in the TDF arm and 304
patients in the ABC arm who fulfilled the abovementioned criteria.
Table 1 shows the demographics, laboratory data, and medical
conditions of the study population at baseline. The majority of the
study population was males, comparatively young and had a small
stature (median weight, 64 kg, median BMI, 22.2 kg/m
2). More
than 80% of the patients in the two arms had ritonavir-boosted PI.
In the ABC arm, patients had significantly lower CD4 count
(p=0.006), were significantly more likely to have hypertension
(p,0.001), and tended to use more nephrotoxic drugs (p=0.109).
On the other hand, in the TDF arm, patients had marginally
higher baseline eGFR (p=0.098) and were significantly more
likely to have hepatitis B virus infection (P,0.001). However, all
other major background parameters were similar in the two
groups (Table 1).
More than 25% decrement in eGFR from baseline occurred in
44 patients (22.1%) in the TDF arm and 41 (13.5%) in the ABC
arm, with an estimated incidence of 9.84 and 4.55 per 100 person-
years, respectively. Figure 1 shows the time from ART initiation to
.25% decrease in eGFR by the Kaplan Meier method in the two
groups. Patients who started TDF-containing ART were signifi-
cantly more likely to develop renal dysfunction, compared to the
ABC group (p=0.001, Log-rank test). The median time from
commencement of ART to occurrence of .25% decrement in
eGFR was 246 days (range, 1–1,339 days) for the TDF arm and
501 days (range, 7–2,022) for ABC arm. The total observation
period was 447.2 patient-years [median, 839 days, interquartile
range (IQR), 357–1137 days] for the TDF arm and 901.7 patient-
years (median, 1,119 days, IQR, 660.5–1509 days) for the ABC
arm.
Univariate analysis showed a significant relationship between
TDF use and .25% decrement in eGFR (HR=1.747; 95%CI,
1.152–2.648; p=0.009) (Table 2). Furthermore, old age, small
body weight, low baseline CD4 count, high HIV viral load, high
eGFR, low serum creatinine, concurrent use of nephrotoxic drugs,
hepatitis B infection, and diabetes mellitus were associated with
renal dysfunction. On the other hand, concurrent use of ritonavir
boosted PIs was not associated with renal dysfunction
(HR=1.220; 95%CI, 0.663–2.244; p=0.523). Multivariate anal-
ysis identified TDF use as a significant risk for .25% decrement in
eGFR after adjustment for age and weight (adjusted HR=1.893;
95%CI, 1.243–2.881; p,0.003) (Table 3, Model 2), and also after
adjustment for other risk factors (adjusted HR=2.080; 95%CI,
1.339–3.232; p,0.001) (Table 3, Model 3). We also conducted a
sensitivity analysis using BMI decrement instead of weight as a
variable in Table 3, Model 3. The results were almost identical;
TDF use over ABC use was a risk for renal dysfunction (adjusted
HR 1.957, 95% CI 1.262–3.036, p=0.003).
Sensitivity analysis with creatinine clearance confirmed the
abovementioned findings: both univariate and multivariate
analyses showed that TDF use was significantly associated with
.25% decrement in eGFR (univariate analysis: HR=2.212;
95%CI, 1.340–3.653; p=0.002) (multivariate analysis: adjusted
HR=2.544; 95%CI, 1.493–4.335; p=0.001).
Subgroup analysis of the patients stratified by intertertile
baseline body weight showed that the lower the baseline body
weight, the more evident the impact of TDF on renal dysfunction
(#60 kg: adjusted HR=2.771; 95%CI, 1.494–5.139; p=0.001)
(61–68 kg: adjusted HR=1.908; 95%CI, 0.764–4.768; p=0.167)
(.68 kg: adjusted HR=0.997; 95%CI, 0.318–3.121; p=0.995)
(Table 4). These findings suggest that there is the effect
modification by baseline body weight on TDF-associated renal
dysfunction.
Data analysis by repeated measures mixed models showed a
significant decrease in adjusted mean eGFR from the baseline to
96 weeks in both groups (TDF: -9.984 ml/min/1.73m
2, 95%CI -
12.05 to -7.914 ml/min/1.73m
2,p ,0.001; ABC: -5.393 ml/min/
1.73m
2, 95%CI -7.087 to -3.699 ml/min/1.73m
2,p ,0.001)
(Figure 2). There was a statistically significant interaction between
the two arms over time (p=0.003), indicating that adjusted mean
eGFR decreased more significantly in the TDF group than in the
ABC group after initiation of ART. Analysis of eGFR in each
group demonstrated a rapid decrease during the first 24 weeks,
TDF Renal Dysfunction in Low Body Weight Patients
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patients who commenced treatment with ABC, those on TDF were more likely to develop .25% fall in eGFR (p=0.001, Log-rank test). TDF: tenofovir,
ABC: abacavir, ART: antiretroviral therapy, eGFR: estimated glomerular filtration rate.
doi:10.1371/journal.pone.0029977.g001
Table 1. Baseline demographics and laboratory data of patients who received tenofovir- and abacavir-based antiretroviral therapy
(n=503).
TDF (n=199) ABC (n=304) P value
Sex (male), n (%) 196 (98.5) 296 (97.4) 0.539
Median (IQR) age 36 (31–44) 37 (31–43) 0.436
Median (IQR) weight (kg) 64 (58–69) 64 (58.0–70.9) 0.426
Median (IQR) BMI (kg/m
2) 22.1 (20.4–23.9) 22.2 (20.3–24.6) 0.321
Median (IQR) eGFR (ml/min/1.73m
2) 119.4 (103.0–135.0) 115.6 (102.4–132.2) 0.098
Median (IQR) serum creatinine (mg/dl) 0.74 (0.67–0.84) 0.75 (0.68–0.83) 0.250
Median (IQR) CD4 count (/ml) 199 (109–272) 178.5 (75.3–234.8) 0.006
Median (IQR) HIV RNA viral load (log10/ml) 4.63 (4.20–5.20) 4.74 (4.23–5.20) 0.731
Ritonavir-boosted protease inhibitors, n (%) 173 (86.9) 256 (84.2) 0.441
Protease inhibitors (unboosted), n (%) 5 (2.5) 20 (6.6) 0.038
NNRTIs, n (%) 16 (8.0) 26 (8.6) 0.848
INIs, n (%) 5 (2.5) 2 (0.7) 0.119
Hypertension, n (%) 5 (2.5) 53 (17.4) ,0.001
Dyslipidemia, n (%) 4 (2.0) 4 (1.3) 0.718
Diabetes mellitus, n (%) 8 (4.0) 12 (3.9) 1.000
Concurrent use of nephrotoxic drugs, n (%) 65 (32.7) 121 (39.8) 0.109
Hepatitis B, n (%) 35 (17.6) 9 (3.0) ,0.001
Hepatitis C, n (%) 7 (3.5) 7 (2.3) 0.421
Current smoker, n (%) 93 (46.7) 149 (49.3) 0.585
TDF: tenofovir, ABC: abacavir, IQR: interquartile range, BMI: body mass index, eGFR: estimated glomerular filtration rate, NNRTI: non- nucleoside reverse transcriptase
inhibitor, INI: integrase inhibitor.
doi:10.1371/journal.pone.0029977.t001
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creatinine clearance calculated by Cockcroft-Gault equation, the
result was the same; a significant decrease from the baseline to 96
weeks in both groups (TDF: -10.62 ml/min, 95%CI -13.78 to
-7.458 ml/min; ABC: -4.325 ml/min, 95%CI -6.893 to
-1.756 ml/min) and significantly more eGFR decrement in the
TDF group (p=0.019).
Discussion
In this observational Japanese cohort, treatment-naı ¨ve patients
who started TDF-containing ART experienced eGFR decline of
.25% approximately twice as likely compared to those treated
with ABC-containing regimen. Univariate and multivariate
analyses identified TDF use as an independent risk factor for
renal dysfunction. Subgroup analysis showed that the effect of
TDF on renal dysfunction was more evident in patients with lower
body weight. Furthermore, eGFR decrement was significantly
larger in the TDF group than in ABC group over the 2-year
observation period.
In our previous study, we demonstrated a high incidence of
TDF-associated nephrotoxicity in patients with low body weight,
and the use of a robust statistical model indicated a greater decline
in renal function in patients of low body weight treated with TDF
[16]. The results of the present study further emphasize the
importance of low body weight as a risk factor for TDF-related
nephrotoxicity by showing that in a cohort of patients with low
body weight, the incidence of renal dysfunction was twice higher
with TDF use than with ABC use.
Among the studies designed to compare renal function after the
commencement of TDF and ABC-containing ART for treatment-
naı ¨ve patients, our cohort had the lowest median body weight (64
kg). This is lower than the median body weight of patients of the
ASSERT study conducted in European countries (72 kg) [10]. The
Table 2. Univariate analysis to estimate the risk of various
factors in inducing more than 25% fall in eGFR.
Hazard ratio 95% CI P value
TDF vs. ABC use 1.747 1.152–2.648 0.009
Female gender 0.048 0.000–16.93 0.310
Age per 1 year 1.031 1.011–1.051 0.002
Weight per 1 kg decrement 1.047 1.023–1.072 ,0.001
BMI per 1 kg/m
2 decrement 1.152 1.066–1.244 ,0.001
CD4 count per 1 /ml decrement 1.006 1.004–1.008 ,0.001
HIV viral load per log10/ml 1.562 1.179–2.071 0.002
Ritonavir-boosted protease inhibitors 1.220 0.663–2.244 0.523
Baseline eGFR per 1 ml/min/1.73m
2 1.009 1.005–1.014 ,0.001
Baseline serum creatinine per 1mg/dl 0.016 0.003–0.086 ,0.001
Concurrent nephrotoxic drug 2.134 1.417–3.214 ,0.001
Hepatitis B 1.866 1.038–3.356 0.037
Hepatitis C 1.721 0.631–4.695 0.289
Diabetes mellitus 2.558 1.181–5.540 0.017
Hypertension 0.865 0.448–1.669 0.664
Current smoking 0.989 0.657–1.489 0.958
eGFR: estimated glomerular filtration rate, CI: confidence interval, TDF:
tenofovir, ABC: abacavir, BMI: body mass index.
doi:10.1371/journal.pone.0029977.t002
Table 3. Multivariate analysis to estimate the risk of TDF- over ABC-based antiretroviral therapy in inducing more than 25% fall in
eGFR.
Model 1 Crude Model 2 Adjusted Model 3 Adjusted
HR 95% CI HR 95%CI HR 95%CI
TDF vs. ABC use
{ 1.747 1.152–2.648 1.893 1.243–2.881 2.080 1.339–3.232
Age per 1 year 1.029 1.010–1.048 1.020 1.000–1.040
Weight per 1 kg decrement
{ 1.046 1.022–1.071 1.028 1.005–1.052
CD4 count per 1 /ml decrement
{ 1.004 1.002–1.007
HIV viral load per log10/ml 1.048 0.749–1.466
Serum creatinine per 1 mg/dl
{ 0.053 0.009–0.304
Use of nephrotoxic drug 1.309 0.825–2.077
Hepatitis B 1.070 0.573–2.000
Diabetes mellitus 1.565 0.684–3.582
{P,0.05 in Model 3.
TDF: tenofovir, ABC: abacavir, eGFR: estimated glomerular filtration rate, HR: hazard ratio, CI: confidence interval.
doi:10.1371/journal.pone.0029977.t003
Table 4. Multivariate analysis to estimate the risk of TDF-
over ABC-based antiretroviral therapy in the induction of
more than 25% fall in eGFR according to baseline body
weight.
Adjusted HR 95% CI
P
value
Baseline body weight #60 kg
(n=171)
TDF vs. ABC use 2.771 1.494–5.139 0.001
Baseline body weight 61–68 kg
(n=167)
TDF vs. ABC use 1.908 0.764–4.768 0.168
Baseline body weight .68 kg
(n=165)
TDF vs. ABC use 0.997 0.318–3.121 0.995
TDF use was adjusted with the same variables indicated in Model 3, Table 3: age
per 1 year, weight per 1 kg decrement, CD4 count per 1 /ml decrement, HIV viral
load per log10/ml, serum creatinine per 1 mg/dl, concurrent use of nephrotoxic
drugs, hepatitis B infection, and diabetes mellitus.
doi:10.1371/journal.pone.0029977.t004
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from the findings of randomized clinical trials that demonstrated
no major change in renal function of TDF- and ABC-treated
patients over 48–96 week follow-up [2,10,11]. The discrepant
results might arise from differences between observational cohort
and clinical trials, since observational studies tend to express the
results in ‘‘real world setting’’ whereas clinical trials include
patients who fulfill more strict criteria, therefore with better profile
[9]. The discrepant results could be also due to the use of different
definitions for renal dysfunction in these studies. However, the
discrepant results could also reflect the difference in median body
weight between the present study and these clinical trials. The
results of our subgroup analysis support this hypothesis by showing
that the effect of TDF on renal dysfunction was more evident in
patients with low body weight. Apart from being low-body-
weighted, the patients in this study did not appear to have many of
other established risks for TDF-related nephrotoxicity; they were
comparatively young, had relatively stable CD4 count, and had
only a few co-morbidities (Table 1). Although the majority
concurrently used ritonavir-boosted PIs, which are a probable risk
for TDF-related nephrotoxicity, ritonavir-boosted PIs were not
significantly associated with renal dysfunction in our cohort
(Table 2) [24].
Changes in eGFR in those patients treated with TDF-
containing ART were characterized by a rapid decline during
the first 24 weeks of therapy, followed by a plateau until 96 weeks
(Fig. 2). This finding is consistent with that reported from the
Johns Hopkins group [9,28]. Together with the finding that the
median time from commencement of ART to the .25% decline
in eGFR in the TDF-treated patients was 246 days, these results
suggest that careful monitoring of renal function is particularly
warranted in the first year of TDF-based therapy. Thus, we
suggest that renal function should be monitored by measurement
of serum creatinine at least once annually in resource-limited
settings and twice annually in resource-rich settings in patients
starting TDF-containing ART, especially those with baseline body
weight ,60 kg.
The Department of Health and Human Services guideline for
the treatment of HIV infection in the U.S. lists ABC as an
alternative NRTI because it can potentially cause serious
hypersensitivity reaction and cardiovascular diseases (URL:http:
//www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf).
However, some international guidelines consider both TDF and
ABC as the preferred NRTIs under the condition that ABC should
beusedwithcautioninpatientswithviralload.100,000 copies/mL,
based on the low incidence of ABC-related hypersensitivity among
HLA-B*5701-negative population and the controversial associ-
ation between ABC and cardiovascular diseases [1,29–32] (URL:
http://www.europeanaidsclinicalsociety.org/images/stories/EACS-
Pdf/1_treatment_of_hiv_infected_adults.pdf) (http://www.haart-support.
jp/guideline2011.pdf. in Japanese). The present study, together
with our previous analysis that demonstrated preferential TDF-
related nephrotoxicity in patients with low body weight,
emphasize the advantage of ABC over TDF with regard to
prognosis of renal function in low body weight patients [16].
TDF is the prodrug of acyclic nucleotide analog tenofovir,
which is excreted by both glomerular filtration and active tubular
secretion. Tenofovir is considered to cause mitochondrial damage
in proximal renal tubular cells [33]. The concentration of
tenofovir in the proximal renal tubules could be augmented with
the complex interactions of pharmacological, environmental, and
genetic factors, including small body weight, consequently
resulting in renal tubular dysfunction [34]. Body weight has been
identified as an important factor in TDF-related nephrotoxicity
not only in clinical trials, but also in in vitro and pharmacokinetic
studies [35–37].
The present study has several limitations. First, because of its
retrospective nature, it was not possible to control the baseline
characteristics of the enrolled patients. Thus, it is possible that
patients with potential risk for TDF-related nephrotoxicity were
not prescribed TDF. A proportion of patients treated with ABC
had low CD4 count and others were hypertensive, both conditions
are known risk factors for renal dysfunction [23,25]. However, for
these reasons, the incidence of TDF-associated renal dysfunction
might have been underestimated. Second, the definition of TDF-
related nephrotoxicity, especially the criteria used to evaluate
proximal renal tubular damage, is not uniformly established in the
field and is different in the published studies. Accordingly, we
Figure 2. Changes in eGFR in patients treated with TDF or ABC between baseline and 96 weeks. The fall in eGFR was significantly greater
in the TDF group than the ABC group (p=0.003). Data are adjusted mean 695% confidence interval. eGFR: estimated glomerular filtration rate, TDF:
tenofovir, ABC: abacavir.
doi:10.1371/journal.pone.0029977.g002
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proximal renal tubular damage. Using the eGFR as a marker for
TDF-associated renal dysfunction, our results might have underes-
timated the incidence of TDF-related renal tubular dysfunction.
However, the result of this study could be informative to resource-
limited settings, where it is difficult to evaluate renal tubular
markers. The rational and limitation of adopting more than 25%
decrement in eGFR as the criterion for renal dysfunction were
discussed in detail in our previous study [16]. Third, our cohort was
characterized by the high prevalence of ritonavir-boosted PI use,
which is considered by some groups a risk for TDF-related
nephrotoxicity [24]. While it is difficult to completely exclude the
impact of concurrent ritonavir-boosted PI in this study, it should be
noted that the use of ritonavir-boosted PIs did not correlate with
renal dysfunction in univariate analysis in this cohort (Table 2).
Fourth, the study subjects were mainly men (mostly men who have
sex with men and very few injection drug users). Further studies are
needed to determine whether the findings of this study are also
applicable to females, patients with different route of transmissions,
and patients of different racial background.
In conclusion, the present study demonstrated a high incidence
of renal dysfunction with TDF use, compared to ABC, among
treatment-naı ¨ve patients with low body weight. TDF use was
identified as an independent risk for renal dysfunction in a
statistical model that included TDF as a primary exposure. At 96
weeks, patients with TDF showed greater eGFR decrement than
patients treated with ABC. TDF is certainly a drug of choice in the
treatment of HIV infection, but the importance of close
monitoring of renal function in patients with small body weight,
especially those with baseline body weight ,60 kg should be
emphasized for early detection of TDF-related nephrotoxicity.
Further studies are warranted to elucidate the long-term prognosis
of renal function with TDF use in patients with low body weight.
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